16th May 2006 07:01
Provexis PLC16 May 2006 PROVEXIS PLC ("Provexis" or the "Company") SircoTM science to be published in leading scientific journal Provexis, the nutraceutical company that develops scientifically-provenfunctional and medical foods, announces a major international scientificendorsement for its lead product SircoTM. Two scientific papers, which detailthe clinical efficacy of SircoTM, are to be published by the American Journal ofClinical Nutrition (AJCN). The AJCN is internationally recognised as thehighest-ranked peer-reviewed journal in the nutrition field. SircoTM, a chilled fruit juice, is the first heart health product to contain thepatented FruitflowTM technology. FruitflowTM is a natural bioactive extract fromtomato that works by reducing blood platelet aggregation within hours ofconsumption. Platelet aggregation plays a significant role in the formation of athrombus (internal blood clot) which can cause a heart attack or stroke. SircoTM is currently available in the UK in the chilled juice category in over550 Tesco and Waitrose stores. The product is targeted at adults who are keen tomaintain cardiovascular health. Commenting on the news of the acceptance by the journal, Dr Stephen Franklin,CEO of Provexis, said: "We are delighted that the science behind FruitflowTM has been accepted forpublication by the highest-ranked peer-reviewed scientific journal in the field.We have remained resolute in our belief that the FruitflowTM technology isworld-class and that this would be recognised by the most stringent scientificreview process in the field of clinical nutrition." "The acceptance of two separate scientific papers, published in thisinternationally accredited journal is a significant milestone for the Companyand an essential precursor to initiating a number of key commercial activities". For further information please contact: Provexis plcDr Stephen Franklin 020 8392 6631 Bell Pottinger Corporate & FinancialEmma Kent 020 7861 3232 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Provexis